Ovid Therapeutics Inc. (OVID): Earnings News

OVID – Reports Q2 EPS loss of $0.57.


Key Facts Surrounding This News Item


  • OVID had returned 0.00% year-to-date leading up to today’s news, versus a +11.63% return from the benchmark S&P 500 during the same period.

More Info About Ovid Therapeutics Inc. (OVID)


Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York. View our full OVID ticker page with ratings, news, and more.

OVID at a Glance

OVID Current POWR Rating™
Overall POWR Rating™
OVID Current Price $10.33 1.15%
More OVID Ratings, Data, and News

OVID Price Reaction

The day of this event (Aug. 10, 2017)
OVID Closing Price$5.32 16.35%
OVID Volume58,900
35.93% from avg
Leading up to this event
OVID 1-mo return29.25%
After this event
OVID 1-day return1.60%
OVID 3-day return2.75%
OVID 5-day return0.16%

OVID Price Chart



More Ovid Therapeutics Inc. (OVID) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All OVID News
Page generated in 0.7886 seconds.